Results 1 to 10 of about 9,572 (201)

Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study [PDF]

International Journal of Emergency Medicine
Background Vernakalant is authorized in several countries, except in the U.S., where the FDA denied its commercialization due to safety concerns, generating debate about its use.
Giuseppe Dominijanni, Antonio F. Caballero-Bermejo, Ana Sainz-Herrero, Álvaro Pineda-Torcuato, Rosa Capilla-Pueyo, Belén Ruiz-Antorán   +5 more
doaj   +4 more sources

Flecainide [PDF]

Reactions Weekly, 2020
National Cancer Institute
  +6 more sources

Reappraising Use of Flecainide for Atrial Fibrillation and Ventricular Arrhythmias in Structural Heart Disease Patients [PDF]

Medicina
Background: Flecainide, a class Ic antiarrhythmic agent, has long been contraindicated in structural heart disease (SHD) due to findings of the Cardiac Arrhythmia Suppression Trial (CAST).
Dimitrios Tsiachris, Sotirios C. Kotoulas, Ioannis Doundoulakis, Christos-Konstantinos Antoniou, Michail Botis, Konstantinos Pamporis, Nikolaos Argyriou, Aikaterini-Eleftheria Karanikola, Panagiotis Tsioufis, Athanasios Kordalis, Konstantinos Tsioufis   +10 more
doaj   +2 more sources

Common Structural Pattern for Flecainide Binding in Atrial-Selective K_v1.5 and Na_v1.5 Channels: A Computational Approach [PDF]

Pharmaceutics, 2022
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its treatment includes antiarrhythmic drugs (AADs) to modulate the function of cardiac ion channels.
Yuliet Mazola, José C. E. Márquez Montesinos, David Ramírez, Leandro Zúñiga, Niels Decher, Ursula Ravens, Vladimir Yarov-Yarovoy, Wendy González   +7 more
doaj   +2 more sources

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial

EBioMedicine, 2015
Background: Abnormalities in membrane excitability and Na+ channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+ channel blocker and membrane ...
Susanna B Park, Steve Vucic, Cindy Shin-Yi Lin   +2 more
exaly   +3 more sources

Flecainide Toxicity Leading to Loss of Pacemaker Capture and Cardiac Arrest

JACC: Case Reports, 2021
An 86-year-old man with paroxysmal atrial fibrillation on flecainide, a class IC antiarrhythmic, presented with cardiac arrest. The patient had extremely wide QRS complexes with inconsistent pacemaker capture on electrocardiography.
Harold Rivner, MD, Litsa K. Lambrakos, MD   +1 more
doaj   +2 more sources

Flecainide

Reactions Weekly
Arunachalam K, Patel P.
europepmc   +11 more sources

A pilot study on the acute conversion and maintenance of sinus rhythm in rheumatic atrial fibrillation using oral flecainide

Indian Heart Journal, 2020
Background: Achievement of sinus rhythm (SR) is an important goal in rheumatic atrial fibrillation (AF). Studies in rheumatic AF have often used amiodarone for rhythm control.
Anindya Ghosh, Aditya Kapoor, Roopali Khanna, Ankit Sahu, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel   +7 more
doaj   +2 more sources

High-dose flecainide for symptomatic relief in paramyotonia congenita/severe neonatal episodic laryngospasm due to SCN4A G1306E: a case report [PDF]

Journal of Medical Case Reports
Background Severe neonatal episodic laryngospasm has been previously reported in multiple patients with the heterozygous pathogenic variant G1306E in SCN4A.
Vanessa Ogueri, Jessica Chong, Melissa Fleming, Kara Simpson, Elizabeth Sherwin, Diana Bharucha-Goebel, Christopher Spurney   +6 more
doaj   +2 more sources

Flecainide mediated sodium channel blockade enhances blood brain barrier integrity and promotes neuroprotection in neuroinflammation. [PDF]

Sci Rep
Sindi M, Klees D, Dobelmann V, Disse P, Weigel H, Lichtenberg S, Ricci R, Thewes L, Deniz-Köseoglu G, Hecker C, Müntefering T, Issberner A, Gruchot J, Hartung HP, Ruck T, Berndt C, Kurz T, Stark H, Küry P, Engelhardt B, Lyck R, Meuth SG, Dietrich M, Albrecht P.   +23 more
europepmc   +3 more sources